Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG potassium channels

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 373, Issue 3, 2006, Pages 212-220

  Kiesecker, Claudia ^a   Alter, Markus ^a   Kathöfer, Sven ^a   Zitron, Edgar ^a   Scholz, Eberhard P ^a   Thomas, Dierk ^a   Kreuzer, Jörg ^a   Katus, Hugo A ^a   Bauer, Alexander ^a   Karle, Christoph A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antidepressant; Arrhythmia; hERG; Long QT syndrome; Potassium channel

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MAPROTILINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; TETRACYCLIC ANTIDEPRESSANT AGENT;

ANIMAL CELL; ARTICLE; ATTENUATION; BINDING AFFINITY; BINDING SITE; BLOOD; CARDIOVASCULAR RISK; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LONG QT SYNDROME; MEASUREMENT; MEMBRANE POTENTIAL; MICROELECTRODE; NONHUMAN; OOCYTE; PROTEIN EXPRESSION; RISK FACTOR; VOLTAGE CLAMP; XENOPUS;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL LINE; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MAPROTILINE; MOLECULAR STRUCTURE; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; PHENYLALANINE; POLYCYCLIC COMPOUNDS; POTASSIUM CHANNEL BLOCKERS; TYROSINE; XENOPUS LAEVIS;

EID: 33744821900     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0068-z     Document Type: Article

References (22)

1. Ahles S, Gwirtsman H, Halaris A, Shah P, Schwarcz G, Hill MA (1984) Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. J Clin Psychiatry 45:460-465
2. Glassman AH, Roose SP (1994) Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revising risks. Gerontology 40 [Suppl 1]:15-20
3. Karle CA, Zitron E, Zhang W, Wendt-Nordahl G, Kathofer S, Thomas D, Gut B, Scholz E, Vahl CF, Katus HA, Kiehn J (2002) Human cardiac inwardly-rectifying K+ channel Kir (2.1b) is inhibited by direct protein kinase C-dependent regulation in human isolated cardiomyocytes and in an expression system. Circulation 106:1493-1499
4. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ (1993) Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 3:13-21
5. Kiehn J, Lacerda AE, Brown AM (1999) Pathways of HERG inactivation. Am J Physiol 277:H199-H210
6. Kiesecker C, Zitron E, Luck S, Bloehs R, Scholz EP, Kathofer S, Thomas D, Kreye VA, Katus HA, Schoels W, Karle CA, Kiehn J (2004) Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. Naunyn-Schmiedebergs Arch Pharmacol 370:423-435
7. Lentini S, Rao ML, Schroder R, Luderitz B, Bauriedel G (2001) QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects. Dtsch Med Wochenschr 126:1396-1400
8. Llerena A, Dorado P, Berecz R, Gonzalez AP, Penas-LLedo EM (2004) Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 59:869-873
9. Madeja M, Musshoff U, Speckmann EJ (1997) Follicular tissues reduce drug effects on ion channels in oocytes of Xenopus laevis. Eur J Neurosci 9:599-604
10. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ (2003) Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139:887-898
11. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333
12. Parker J, Lahmeyer H (1984) Maprotiline poisoning: a case of cardiotoxicity and myoclonic seizures. J Clin Psychiatry 45:312-314
13. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45
14. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC (2002) Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 277:23587-23595
15. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC (2003) Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 63:1051-1058
16. Scholz EP, Zitron E, Kiesecker C, Luck S, Thomas D, Kathofer S, Kreye VA, Katus HA, Kiehn J, Schoels W, Karle CA (2005) Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn-Schmiedebergs Arch Pharmacol 371:516-525
17. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ (1999) Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128:479-485
18. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300:543-548
19. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC (2002) Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 512:59-66
20. Zitron E, Karle CA, Wendt-Nordahl G, Kathofer S, Zhang W, Thomas D, Weretka S, Kiehn J (2002) Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol 137:221-228
21. Zitron E, Kiesecker C, Scholz E, Luck S, Bloehs R, Kathofer S, Thomas D, Kiehn J, Kreye VA, Katus HA, Schoels W, Karle CA (2004) Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn-Schmiedebergs Arch Pharmacol 370:146-156
22. Zuchner H (2002) QT prolongation and torsade de pointes - tachycardia in therapy with maprotiline. Dtsch Med Wochenschr 127:983-984